RxDoctor Payments DataLook up a doctor →

Courtney Elliot

Nurse Practitioner · Cushing, OKNPI 1538182555

Payments from drug & device makers

$6,239in general payments, 2019–2025

Across 368 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$822
  • GSK$472
  • Lilly USA, LLC$401
  • Axsome Therapeutics, Inc.$280
  • Mylan Specialty L.p.$227
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,13998%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,239 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$119,718
Medicare patients
359
Services billed
13,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide90$108,156
OzempicSemaglutide46$53,570
TrulicityDulaglutide33$43,573
XareltoRivaroxaban52$33,926
EliquisApixaban22$17,814
JanuviaSitagliptin Phosphate19$15,477
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$12,211
Tresiba Flextouch U-200Insulin Degludec21$8,063
MyrbetriqMirabegron16$7,090
Combivent RespimatIpratropium/Albuterol Sulfate12$6,046
Omeprazole187$2,832
Duloxetine Hcl164$2,190
Celecoxib36$2,058
Pantoprazole Sodium138$2,011
Atorvastatin Calcium162$1,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$401$151,728123 claims
Novo NordiskOzempic$169$53,57046 claims
Johnson & JohnsonXarelto$112$33,92652 claims
PfizerEliquis$200$17,81422 claims
MerckJanuvia$161$15,47719 claims
Astellas Pharma US IncMyrbetriq$135$7,09016 claims
Boehringer IngelheimCombivent Respimat$197$6,04612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Cushing

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →